US equities
|
INTC
$119.13
▼-0.17%
MU
$1,074.89
▲+0.00%
NVDA
$233.95
▲+0.00%
SNDK
$1,719.99
▲+0.00%
SDEV
$7.48
▲+0.00%
SPCX
$158.96
▲+0.00%
AMD
$633.91
▲+0.00%
TSLA
$370.59
▲+0.00%
INTC
$119.13
▼-0.17%
MU
$1,074.89
▲+0.00%
NVDA
$233.95
▲+0.00%
SNDK
$1,719.99
▲+0.00%
SDEV
$7.48
▲+0.00%
SPCX
$158.96
▲+0.00%
AMD
$633.91
▲+0.00%
TSLA
$370.59
▲+0.00%
FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
InMed Pharmaceuticals Inc. - Common Shares
(NQ:
INM
)
1.330
UNCHANGED
Delayed Quote
Updated: 4:00 PM EDT, Oct 2, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about InMed Pharmaceuticals Inc. - Common Shares
< Previous
1
2
...
9
10
11
12
13
14
15
16
Next >
BioMedNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Announces Board Appointment, Changes
August 09, 2022
Via
Investor Brand Network
BioMedNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Issues Update on Phase 2 EB Trial
July 25, 2022
Via
Investor Brand Network
InMed Provides An Update On Phase 2 Clinical Trial Investigating Cannabinol Cream For Epidermolysis Bullosa
↗
July 25, 2022
InMed Pharmaceuticals Inc. (NASDAQ: INM) provided an update on its phase 2 clinical trial using investigational drug INM-755 cannabinol (“CBN”) cream for the treatment
Via
Benzinga
BioMedNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Appoints Michael Woudenberg as Chief Operating Officer
July 18, 2022
Via
Investor Brand Network
Why Bank Stocks Traded Sharply Higher; Here's 65 Biggest Movers From Friday
↗
July 18, 2022
Gainers United Maritime Corporation (NASDAQ: USEA) shares climbed 175.9% to close at $6.07 on Friday. United Maritime, on Tuesday, announced acquisition of four oil tankers and filed for stock offering...
Via
Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday
↗
July 15, 2022
Good morning! We're starting the last day of trading this week with a breakdown of the biggest pre-market stock movers for Friday!
Via
InvestorPlace
Citigroup, Bank of America And 48 Stocks Moving In Friday's Mid-Day Session
↗
July 15, 2022
Gainers United Maritime Corporation (NASDAQ: USEA) shares jumped 180.9% to $6.19. United Maritime, on Tuesday, announced acquisition of four oil tankers and filed for stock offering on Wednesday.
Via
Benzinga
Why Is Pinterest Higher By 14%? 20 Stocks Moving In Friday's Pre-Market Session
↗
July 15, 2022
Gainers United Maritime Corporation (NASDAQ: USEA) rose 55% to $3.41 in pre-market trading. United Maritime, on Tuesday, announced acquisition of four oil tankers and filed for stock offering on...
Via
Benzinga
BayMedica LLC: Working With Cannabis Multi-State Operators To Make Their Products Better
↗
July 05, 2022
InMed Pharmaceuticals Inc. (NASDAQ: INM), a leader in the research, development, manufacturing and commercialization of rare cannabinoids, is taking a leading position in the marketplace.
Via
Benzinga
Marijuana As An Appetite Suppressant? It's A Possibility
↗
June 30, 2022
Using cannabis as an appetite suppressant for weight management may seem counterintuitive, but one rare cannabinoid may have just that effect. Delta-9 (d-9)-dominant tetrahydrocannabivarin (THCV) has...
Via
Benzinga
InMed Pharmaceuticals: The Clinical-Stage Company Setting Sites On Dominating Rare Cannabinoid Production And Commercialization Across Global Markets
↗
June 23, 2022
Shane Johnson, SVP and General Manager of Baymedica of InMed Pharmaceuticals (NASDAQ: INM), was a guest speaker at Benzinga’s All Access on June 17th, 2022.
Via
Benzinga
CannabisNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Announces Results of Peer-Reviewed Study Published in International Journal
June 14, 2022
Via
Investor Brand Network
CannabisNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Announces Results of Peer-Reviewed Study Published in International Journal
June 14, 2022
Via
CannabisNewsWire
InMed Publishes Study On Potential Role Of Rare Cannabinoids For Skin Conditions
↗
June 14, 2022
InMed Pharmaceuticals Inc. (NASDAQ: INM) announced that a peer-reviewed scientific study entitled “Effects of Rare Phytocannabinoids on the Endocannabinoid System of Human Keratinocytes” has been...
Via
Benzinga
BioMedNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Expands Portfolio of Rare Cannabinoids with Launch of d9-THCV
June 09, 2022
Via
Investor Brand Network
Topics
Economy
Supply Chain
CannabisNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Closes $5M Direct, Private Placement Offerings
June 07, 2022
Via
CannabisNewsWire
CannabisNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Closes $5M Direct, Private Placement Offerings
June 07, 2022
Via
Investor Brand Network
CannabisNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Announces $5M Registered Direct and Private Placement Offerings
June 02, 2022
Via
CannabisNewsWire
CannabisNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Announces $5M Registered Direct and Private Placement Offerings
June 02, 2022
Via
Investor Brand Network
InMed Pharmaceuticals Announces $5 Million Registered Direct And Private Placement Offerings
↗
June 02, 2022
InMed Pharmaceuticals Inc. (NASDAQ: INM) has entered into securities purchase agreements with a single healthcare-focused institutional investor for the issuance and sale of 4.08 million of its common...
Via
Benzinga
InMed Pharmaceuticals Is Commercializing The Development Of Rare Cannabinoids For The Wellness Market
↗
May 17, 2022
Upon its acquisition of BayMedica LLC last year, InMed Pharmaceuticals Inc. (Nasdaq: INM) made the executive decision to forge a new path alongside its traditional domain in pharmaceutical drug...
Via
Benzinga
InMed Pharmaceuticals Reports Net Sales Of $575K For 6 Months Since BayMedica Acquisition
↗
May 13, 2022
InMed Pharmaceuticals Inc. (NASDAQ:INM), a leader in research, development, manufacturing and commercialization of rare cannabinoids, released unaudited financial results for the third quarter of the...
Via
Benzinga
BioMedNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Announces Q3 Fiscal 2022 Financial Results, Provides Business Update
May 13, 2022
Via
Investor Brand Network
Topics
Economy
CannabisNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Leveraging Advantage in Rare Cannabinoid Biosynthesis Space
May 09, 2022
Via
Investor Brand Network
Topics
Supply Chain
CannabisNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Leveraging Advantage in Rare Cannabinoid Biosynthesis Space
May 09, 2022
Via
CannabisNewsWire
Topics
Supply Chain
InMed Commercializes Rare Cannabinoids For Health And Wellness Market
↗
May 09, 2022
This post contains sponsored advertising content. This content is for informational purposes only and is not intended to be investing advice.
Via
Benzinga
BioMedNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) to Participate in Groundbreaking Study with Trokie and Radicle Science
May 05, 2022
Via
Investor Brand Network
BioMedNewsBreaks – InMed Pharmaceuticals Inc.’s (NASDAQ: INM) Transition from Pure-Play Pharma R&D Firm Featured in Research Report
May 04, 2022
Via
Investor Brand Network
InMed Pharmaceuticals (INM): Notable Launches of High-Value Rare Cannabinoids
May 03, 2022
Our newswire features a comprehensive, flat-fee Press Release service. Generate quality engagement with real-time analytics to improve visibility and expand your influence.
From
Edison Investment Research Limited
Via
AccessWire
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
↗
May 03, 2022
It's time for another dive into the biggest pre-market stock movers for today as we prepare for a busy day of trading on Tuesday!
Via
InvestorPlace
< Previous
1
2
...
9
10
11
12
13
14
15
16
Next >
